NVO•benzinga•
Novo Nordisk, Deep Apple Launch Drug Discovery Alliance For Weight Loss Oral Therapies
Summary
Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 11, 2025 by benzinga